[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][C@H1][Branch1][=Branch1][C][N][C][Ring1][=Branch1][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=C][C][=C][C][=C][Branch1][#Branch1][C][Ring1][=Branch1][=N][Ring1][=Branch2][C][=Branch1][C][=O][N]"}, {"from": "gpt", "value": "The molecule is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019."}]